464 related articles for article (PubMed ID: 29115660)
1. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
2. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Gao L; Liu F; Zhang H; Sun J; Ma Y
Genes Chromosomes Cancer; 2016 Feb; 55(2):158-68. PubMed ID: 26542416
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
4. Methylation of gene CHFR promoter in acute leukemia cells.
Gong H; Liu W; Zhou J; Xu H
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
[TBL] [Abstract][Full Text] [Related]
5. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
6. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.
Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM
Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300
[TBL] [Abstract][Full Text] [Related]
7. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
8. Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia.
Zhang ZH; Zhang W; Zhou JD; Zhang TJ; Ma JC; Xu ZJ; Lian XY; Wu DH; Wen XM; Deng ZQ; Lin J; Qian J
Mol Carcinog; 2018 Jun; 57(6):735-744. PubMed ID: 29457658
[TBL] [Abstract][Full Text] [Related]
9. Abnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia.
Nan FY; Gu Y; Xu ZJ; Sun GK; Zhou JD; Zhang TJ; Ma JC; Leng JY; Lin J; Qian J
Cancer Med; 2021 Aug; 10(15):5283-5296. PubMed ID: 34227248
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
[TBL] [Abstract][Full Text] [Related]
11. [Aberrant promoter hypermethylation of CHFR in nasopharyngeal carcinoma].
Huang T; Du C; Yu N; Xiao X; Zhou X; Wang S; Huang G; Zhang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Aug; 25(16):746-50. PubMed ID: 22070084
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
13. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
[TBL] [Abstract][Full Text] [Related]
14. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of SRY-box containing gene family member
Zhou JD; Wang YX; Zhang TJ; Li XX; Gu Y; Zhang W; Ma JC; Lin J; Qian J
Clin Epigenetics; 2018; 10():92. PubMed ID: 30002740
[TBL] [Abstract][Full Text] [Related]
18. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Li M; Gao L; Li Z; Sun J; Zhang H; Duan H; Ma Y; Wang C
Oncotarget; 2016 May; 7(21):31454-65. PubMed ID: 27129146
[TBL] [Abstract][Full Text] [Related]
19. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia.
Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; An C; Tang CY; Qian Z; Liu Q
Leuk Res; 2014 May; 38(5):613-8. PubMed ID: 24685333
[TBL] [Abstract][Full Text] [Related]
20. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]